Clinical trials for BioNTech’s cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market, the German company’s top executive Ugur Sahin told magazine Der Spiegel.
The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals Inc.’s drug to treat an advanced eye disorder that is one of the leading causes of blindness globally, the company said on Friday.
Becton Dickinson’s C.R. Bard Inc. on Friday won a ruling from a U.S. appeals court reinstating three patents related to its PowerPort devices for delivering repeated medical injections.
The U.S. government will select the 10 costliest prescription medicines to Medicare for negotiating prices with drugmakers starting early next year, the program’s top official said on Friday.
The race for an influenza vaccine is heating up as Moderna announced mixed interim results for its seasonal flu vaccine candidate Thursday.
One-year data from a Phase II study of Newron’s schizophrenia candidate evenamide showed sustained efficacy and continued improvements in symptoms of psychosis and disease severity.
The decision could delay the time to approval of a vaccine that Valneva expects could become a blockbuster shot as infections rise globally due to a burgeoning population of ticks, which usually cause Lyme disease.
The FDA said the silicon foam used in some reworked ventilator models may separate from plastic backing due to adhesive failure and can reduce the air flow as well as cause debris contamination. The issue can lead to patient injury or death.
Lawyers for a man who alleges he developed bladder cancer after taking GSK Plc’s heartburn drug Zantac urged a California judge on Thursday to allow expert testimony linking the drug to the illness at an upcoming trial.
Pfizer and BioNTech sued Moderna in London in September, seeking to revoke two of Moderna’s patents in relation to its messenger RNA (mRNA) vaccines.
